387
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Emerging drugs for levodopa-induced dyskinesia

, &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Sheilla Da Silva Barroso, Lorenna Emília Sena Lopes, Klebson Silva Santos & Margarete Zanardo Gomes. (2019) Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias. Expert Opinion on Therapeutic Patents 29:12, pages 979-985.
Read now
Nataša Dragašević-Mišković, Igor Petrović, Iva Stanković & Vladimir S. Kostić. (2019) Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy 20:2, pages 219-230.
Read now
Pinky Agarwal, Sudeshna Ray, Daniel Burdick, Alida F Griffith & Arina Madan. (2018) Efficacy and safety of ADS-5102 (amantadine) extended-release capsules for treating levodopa-induced dyskinesia. Expert Opinion on Orphan Drugs 6:10, pages 625-634.
Read now
Giulio Lancioni, Nirbhay Singh, Mark O'Reilly, Jeff Sigafoos, Fiora D'Amico, Giovanni Sasanelli, Floriana Denitto & Russell Lang. (2016) Technology-aided leisure and communication: Opportunities for persons with advanced Parkinson’s disease. Developmental Neurorehabilitation 19:6, pages 398-404.
Read now
Jonathan Tomas Lockwood & Gary Remington. (2015) Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. Expert Opinion on Emerging Drugs 20:3, pages 407-421.
Read now

Articles from other publishers (4)

Pedro Merino. 2019. Chemical Biology of Neurodegeneration. Chemical Biology of Neurodegeneration 325 357 .
M Ba, W Ding, L Guan, Y Lv & M Kong. (2018) S-nitrosylation of Src by NR2B-nNOS signal causes Src activation and NR2B tyrosine phosphorylation in levodopa-induced dyskinetic rat model. Human & Experimental Toxicology 38:3, pages 303-310.
Crossref
Maryka Quik, James T Boyd, Tanuja Bordia & Xiomara Perez. (2019) Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders. Nicotine & Tobacco Research 21:3, pages 357-369.
Crossref
Maryka Quik, Tanuja Bordia, Danhui Zhang & Xiomara A. Perez. 2015. Nicotine Use in Mental Illness and Neurological Disorders. Nicotine Use in Mental Illness and Neurological Disorders 247 271 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.